Evidence map›Paper›PMID 42835109›Full record

ArticleFrontiers in pharmacology2026

Rhenium(I) tricarbonyl complexes with 1,10-phenanthroline derivatives: potential anticancer agents for hepatocellular carcinoma.

César Zúñiga, Diego Oyarzún, Carlos Cardoso, Valentina Melo, Ignacio Montorfano, Yolanda Prado, Felipe Simon, Juan F Santibáñez, Rodrigo Ramírez-Tagle, Javier Echeverría and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

César ZúñigaInstituto de Ciencias Naturales, Facultad de Medicina Veterinaria y Agronomía, Universidad de Las Américas, Santiago, Chile.
Diego OyarzúnDepartamento de Química y Biología, Facultad de Ciencias Naturales, Universidad de Atacama, Copiapó, Chile.
Carlos CardosoATACAMA-OMICS, Laboratorio de Biología Molecular y Genómica, Facultad de Medicina, Universidad de Atacama, Copiapó, Chile.
Valentina MeloATACAMA-OMICS, Laboratorio de Biología Molecular y Genómica, Facultad de Medicina, Universidad de Atacama, Copiapó, Chile.
Ignacio MontorfanoInstituto de Ciencias Naturales, Facultad de Medicina Veterinaria y Agronomía, Universidad de Las Américas, Santiago, Chile.
Yolanda PradoCenter for Research on Pandemic Resilience, Faculty of Life Sciences and Institute of Public Health, Universidad Andres Bello, Santiago, Chile.
Felipe SimonCenter for Research on Pandemic Resilience, Faculty of Life Sciences and Institute of Public Health, Universidad Andres Bello, Santiago, Chile.
Juan F SantibáñezCentro Integrativo de Biología y Química Aplicada (CIBQA), Universidad Bernardo O'Higgins, Santiago, Chile.
Rodrigo Ramírez-TagleFacultad de Ingeniería y Arquitectura, Universidad Central de Chile, Santiago, Chile.
Javier EcheverríaDepartamento de Ciencias del Ambiente, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile.
César EcheverríaInstituto de Ciencias Naturales, Facultad de Medicina Veterinaria y Agronomía, Universidad de Las Américas, Santiago, Chile.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC) is a highly lethal malignancy with limited therapeutic options for advanced disease, motivating the development of metal-based agents that can bypass resistance and improve tumor selectivity. Purpose: This study aimed to evaluate rhenium(I) tricarbonyl complexes bearing 1,10-phenanthroline derivatives, with emphasis on Materials and Methods: Complexes Results and Discussion: Re(3) showed pronounced, selective cytotoxicity (IC Conclusion: Collectively, Re(3) functions as a tuned redox-active agent, triggering apoptosis through the intrinsic pathway. This process possibly involves mitochondrial modulation with tumor selectivity, supporting its advancement as a lead rhenium-based prototype for HCC and motivating

Indexed as

apoptosiscaspasescytotoxicityhepatocellular carcinomarhenium complexes

Identifiers

PMID42835109
PMCPMC13635290

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.